Related Experiment Video
Updated: Nov 9, 2025
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer
Sarah I M Sutherland1,2,3,4, Xinsheng Ju1,2, L G Horvath2,4,5
1Dendritic Cell Research, ANZAC Research Institute, Concord, NSW, Australia.
Abstract:
Tumors evade the immune system though a myriad of mechanisms. Using checkpoint inhibitors to help reprime T cells to recognize tumor has had great success in malignancies including melanoma, lung, and renal cell carcinoma. Many tumors including prostate cancer are resistant to such treatment. However, Sipuleucel-T, a dendritic cell (DC) based immunotherapy, improved overall survival (OS) in prostate cancer. Despite this initial success, further DC vaccines have failed to progress and there has been limited uptake of Sipuleucel-T in the clinic. We know in prostate cancer (PCa) that both the adaptive and the innate arms of the immune system contribute to the immunosuppressive environment. This is at least in part due to dysfunction of DC that play a crucial role in the initiation of an immune response. We also know that there is a paucity of DC in PCa, and that those there are immature, creating a tolerogenic environment. These attributes make PCa a good candidate for a DC based immunotherapy. Ultimately, the knowledge gained by much research into antigen processing and presentation needs to translate from bench to bedside. In this review we will analyze why newer vaccine strategies using monocyte derived DC (MoDC) have failed to deliver clinical benefit, particularly in PCa, and highlight the emerging antigen loading and presentation technologies such as nanoparticles, antibody-antigen conjugates and virus co-delivery systems that can be used to improve efficacy. Lastly, we will assess combination strategies that can help overcome the immunosuppressive microenvironment of PCa.
Insights
Dendritic cell (DC) immunotherapy shows promise for prostate cancer (PCa) by improving survival. However, newer strategies using monocyte-derived DCs (MoDC) have faced challenges, necessitating advanced antigen delivery and combination therapies for better efficacy.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Tumors employ diverse mechanisms to evade immune surveillance, with checkpoint inhibitors showing success in several cancers but resistance in prostate cancer (PCa).
- Sipuleucel-T, a dendritic cell (DC) immunotherapy, demonstrated improved overall survival (OS) in PCa, yet subsequent DC vaccine development has stalled, limiting clinical application.
- Prostate cancer (PCa) exhibits an immunosuppressive microenvironment driven by both adaptive and innate immunity, characterized by dysfunctional and immature DCs, creating a tolerogenic milieu.
Purpose of the Study:
- To review the reasons behind the limited clinical success of newer monocyte-derived DC (MoDC) vaccine strategies in PCa.
- To highlight advanced antigen loading and presentation technologies for enhancing DC vaccine efficacy.
- To explore combination strategies to counteract the immunosuppressive tumor microenvironment in PCa.
Main Methods:
- Review of existing literature on DC-based immunotherapies for prostate cancer.
- Analysis of factors contributing to the failure of MoDC vaccines.
- Evaluation of emerging antigen delivery systems (nanoparticles, antibody-antigen conjugates, virus co-delivery).
Main Results:
- While Sipuleucel-T showed initial OS benefit, further DC vaccine progress has been limited.
- Dysfunctional and immature DCs in PCa contribute to an immunosuppressive and tolerogenic environment.
- Emerging technologies offer potential to improve antigen presentation and DC vaccine efficacy.
Conclusions:
- Prostate cancer (PCa) remains a viable candidate for DC-based immunotherapy due to its inherent immune-suppressive characteristics.
- Advanced antigen loading and presentation technologies are crucial for overcoming current limitations in MoDC vaccine efficacy.
- Combination strategies are essential to address the immunosuppressive tumor microenvironment and enhance therapeutic outcomes in PCa.
More Related Videos
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
01:51Vaccinations